Back

Effects of a novel low-dose triple combination on blood pressure variability: results from the TRIDENT trial

30 August 2026 (08:35 - 08:45)
Organised by: Logo
Congress Presentation Part of: Treatment of hypertension Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Tian Wang

The George Institute for Global Health, Sydney (Australia)

5 More presentations in this session

Presentation thumbnail
Zilebesiran in combination with a diuretic in patients with uncontrolled hypertension: a subgroup analysis from the Phase 2 KARDIA-3 trial
Doctor N. Pagidipati (Durham, US)
Abstract Slides
Presentation thumbnail
Heart failure and uncontrolled hypertension: recent evidence of routine care in Germany
Professor J. Weil (Luebeck, DE)
Abstract Slides
Presentation thumbnail
Effects of intensive blood pressure control across the spectrum of renal impairment: a post hoc analysis from ESPRIT
Doctor S. Li (Beijing, CN)
Abstract Slides
Presentation thumbnail
Differences of the characteristics of uncontrolled versus controlled hypertensive patients, treated with at least three antihypertensive drugs: insights from the SNAPSHOT Europe study
Professor M. Camafort (Barcelona, ES)
Abstract Slides
Presentation thumbnail
Efficacy and safety of potassium-enriched salt substitutes in hypertension management: a systematic review and meta-analysis
Mr T. Bonafe (Varzea Grande, BR)
Abstract Slides

Access the full session

Session thumbnail
Treatment of hypertension
Video

The Event

Event poster

ESC Congress 2026

30 August 2026 08:35 CET
You may be interested in
thumbnail
Congress Presentation
The significance of 24h blood pressure variability improvement regarding target organ damage indices three years after medical treatment initiation in essential hypertension
31 August 2019
thumbnail
Congress Presentation
Single-pill low-dose triple combination therapy versus standard-dose monotherapy in patients with mild to moderate hypertension: results from two randomized clinical trials
30 August 2025
thumbnail
Congress Presentation
Efficacy and safety of various doses of the new dual endothelin receptor antagonist aprocitentan in the treatment of hypertension
31 August 2019
thumbnail
Congress Presentation
External applicability of blood pressure-lowering drug trials to real-world patients with manifest cardiovascular disease
28 August 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources